Phase II Multicenter Study of the Combination of Weekly Carboplatin and Paclitaxel as First-line Chemotherapy for Elderly Patients With Ovarian Cancer.
This is a phase II multicenter study. The experimental treatment is carboplatin (AUC 2) and
paclitaxel 60 mg/m2, on days 1, 8 and 15 every 28 days.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response rate
Sandro Pignata, M.D., Ph.D
National Cancer Institute, Naples
Italy: Ethics Committee